Proposed biosimilar pegfilgrastim LA-EP2006 shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects

被引：0
|
作者：
Nakov, Roumen
Gattu, Sreekanth
Wang, Jessie
Velinova, Maria
Skerjanec, Andrej
机构：
[1] Hexal AG, Holzkirchen, Germany
[2] Sandoz Inc, Princeton, NJ USA
[3] PRA Hlth Sci, Groningen, Netherlands
[4] Sandoz AG, Basel, Switzerland
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-14-10
引用
下载
收藏
页数：1
相关论文
共 46 条
  • [31] Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males
    Vogg, Barbara
    Poetzl, Johann
    El Galta, Rachid
    Fuhr, Rainard
    Schwebig, Arnd
    Sekhar, Susmit
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (1-2) : 91 - 100
  • [32] A pharmacokinetics and pharmacodynamics equivalence trial of proposed pegfilgrastim biosimilar, MYL-1401H vs EU-Neulasta® and US-Neulasta®
    Waller, C.
    Tiessen, R.
    Lawrence, T.
    Shaw, A.
    Liu, M.
    Sharma, R.
    Baczkowski, M.
    Kothekar, M.
    Dias, R.
    Barve, A.
    Pennella, E.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S41 - S41
  • [33] Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy
    Kalpna Desai
    Priya Misra
    Sanyukta Kher
    Nirmesh Shah
    Experimental Hematology & Oncology, 7
  • [34] Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy
    Desai, Kalpna
    Misra, Priya
    Kher, Sanyukta
    Shah, Nirmesh
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2018, 7
  • [35] A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics
    Bellon, Anne
    Wang, Jessie
    Skerjanec, Andrej
    Velinova, Maria
    Dickerson, Daniel
    Sabet, Ahad
    Ngo, Ly
    O'Reilly, Terry
    Tomek, Charles
    Schussler, Steven
    Schier-Mumzhiu, Stefanie
    Gattu, Sreekanth
    Koch, Sven D.
    Schelcher, Celine
    Dobreva, Miryana
    Boldea, Anca
    Nakov, Roumen
    Otto, Gordon P.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (06) : 1139 - 1149
  • [36] A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects
    Tan Zhang
    Guihong Chen
    Chang Liu
    Li’an Zu
    Qi Wang
    Yitong Wang
    Jie Lv
    Youzhong An
    Lihou Dong
    Huiyang Cheng
    Shengbin Ren
    Qian Wang
    Qingshan Zheng
    Haifeng Song
    Yi Fang
    BioDrugs, 2019, 33 : 93 - 100
  • [37] A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects
    Zhang, Tan
    Chen, Guihong
    Liu, Chang
    Zu, Li'an
    Wang, Qi
    Wang, Yitong
    Lv, Jie
    An, Youzhong
    Dong, Lihou
    Cheng, Huiyang
    Ren, Shengbin
    Wang, Qian
    Zheng, Qingshan
    Song, Haifeng
    Fang, Yi
    BIODRUGS, 2019, 33 (01) : 93 - 100
  • [38] LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects
    Lee, Heechan
    Chung, Hyewon
    Lee, SeungHwan
    Lee, Howard
    Yang, Sung Mo
    Yoon, Seo Hyun
    Cho, Joo-Youn
    Jang, In-Jin
    Yu, Kyung-Sang
    BIODRUGS, 2017, 31 (04) : 349 - 355
  • [39] LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects
    Heechan Lee
    Hyewon Chung
    SeungHwan Lee
    Howard Lee
    Sung Mo Yang
    Seo Hyun Yoon
    Joo-Youn Cho
    In-Jin Jang
    Kyung-Sang Yu
    BioDrugs, 2017, 31 : 349 - 355
  • [40] Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity
    Kang, Jia
    Eudy-Byrne, Rena J.
    Mondick, John
    Knebel, William
    Jayadeva, Girish
    Liesenfeld, Karl-Heinz
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (11) : 2274 - 2285
12345